On This Page (5 sections)
Albuterol 5 mg + Ipratropium 0.5 mg continuous nebulization x 3 doses
Dexamethasone 10–16 mg IV/PO OR Methylprednisolone 60–125 mg IV immediately
2g IV in 100 mL saline infused over 15–20 minutes for severe bronchospasm
0.3–0.5 mg IM (1:1,000) anterolateral thigh for refractory bronchospasm
IPAP 10–12 cmH2O, EPAP 4–5 cmH2O; titrate to target SpO2 88–92%
Staged by post-bronchodilator FEV1 (GOLD 1 >=80%, GOLD 2 50-79%, GOLD 3 30-49%, GOLD 4 <30%); acute exacerbations treated with systemic corticosteroids, short-acting bronchodilators, and antibiotics if purulent sputum.
Recurrent spontaneous pneumothorax occurring in reproductive-age females within 48-72 hours of menses onset, caused by thoracic endometriosis with diaphragmatic endometrial implants.
Bottom-Line Clinical Pearl
Acute obstructive respiratory failure kills through dynamic hyperinflation, auto-PEEP, and respiratory muscle exhaustion. Recognize the 'silent chest': the absence of wheezing indicates near-fatal airway obstruction. In acute severe asthma, administer continuous albuterol, ipratropium, IV dexamethasone, and IV magnesium sulfate (2g over 15 min); use IM epinephrine for refractory arrest. In COPD exacerbation, BiPAP reduces intubation rates by 60% and mortality by 40%. If mechanical ventilation is mandatory, target permissive hypercapnia and prolonged expiratory times (I:E 1:4 to 1:5) to prevent tension pneumothorax.
Both acute asthma and COPD exacerbations involve severe expiratory airflow limitation, mucosal edema, and smooth muscle bronchospasm. The mechanical consequence is dynamic hyperinflation (air trapping): patients cannot fully exhale before the next inhalation begins, generating intrinsic positive end-expiratory pressure (Auto-PEEP). Auto-PEEP dramatically increases work of breathing, decreases venous return to the heart, and creates high risk for tension pneumothorax.
| Clinical Finding | Mild-to-Moderate Exacerbation | Severe Exacerbation | Impending Respiratory Arrest (Near-Fatal) |
|---|---|---|---|
| Breath Sounds | Moderate expiratory wheezing | Bilateral inspiratory and expiratory wheezes | SILENT CHEST (no audible air entry; ominous sign of complete occlusion) |
| Speech | Full sentences | Partial phrases (1–3 words) | Inability to speak; profound agitation or lethargy |
| Accessory Muscle Use | Minimal/none | Moderate intercostal and sternocleidomastoid retractions | Paradoxical thoracoabdominal movement; severe exhaustion |
| Mental Status | Alert | Agitated, distressed, sitting upright (tripod position) | Drowsy, confused, obtunded (carbon dioxide narcosis) |
| Blood Gas (ABG/VBG) | Respiratory alkalosis (PaCO2 < 35 mmHg; tachypneic) | Normal PaCO2 (38–42 mmHg; 'pseudonormalization') | Profound respiratory acidosis (PaCO2 > 50 mmHg, pH < 7.25) |
Critical Pitfall / Contraindication
The Pseudonormal PaCO2 Danger: In an acutely tachypneic asthmatic, hyperventilation should drive PaCO2 down into the 20s or low 30s. A 'normal' PaCO2 (40 mmHg) in a dyspneic asthmatic is NOT reassuring: it signals severe respiratory muscle fatigue and impending catastrophic arrest. Prepare for advanced airway management and escalate bronchodilator therapy immediately.
| Therapy Tier | Medication & Dose | Route & Administration | Mechanisms & High-Yield Pearls |
|---|---|---|---|
| First-Line (Bronchodilator) | Albuterol 2.5–5 mg + Ipratropium 0.5 mg (DuoNeb) | Nebulized continuously or q20min x 3 doses | Beta-2 agonist (smooth muscle relaxation) + Anticholinergic (reduces vagal bronchoconstriction and mucus). |
| First-Line (Steroid) | Dexamethasone 10–16 mg PO/IV OR Methylprednisolone 60–125 mg IV | IV or PO immediately upon ED arrival | Decreases late-phase inflammatory cascade and mucosal edema. Onset is 4–6 hours; early administration is vital. |
| Second-Line (Smooth Muscle Relaxant) | Magnesium Sulfate 2g | IV piggyback in 100 mL D5W over 15–20 minutes | Competes with calcium entry into bronchial smooth muscle; reduces hospital admission in severe asthma. |
| Third-Line (Parenteral Catecholamine) | Epinephrine 0.3–0.5 mg (1:1,000) | IM anterolateral thigh q15–20min x 3 doses | Indicated when severe bronchospasm prevents inhaled aerosol delivery to peripheral airways. Highly effective in young asthmatics. |
| Refractory Bronchodilator | Terbutaline 0.25 mg | SubQ q20min x 3 doses | Selective beta-2 agonist; alternative to epinephrine in severe bronchospasm. |
| Refractory Dissociation | Ketamine 1.0–1.5 mg/kg IV | Slow IV push over 2 minutes | Potent bronchodilator via catecholamine release and NMDA antagonism. Facilitates BiPAP compliance or pre-intubation sedation. |
In Acute Exacerbations of COPD (AECOPD), non-invasive positive pressure ventilation (BiPAP) is standard of care for acute hypercapnic respiratory failure (PaCO2 > 45 mmHg, pH < 7.35). It offloads respiratory muscles, improves alveolar ventilation, and dramatically decreases intubation rates and mortality.
| BiPAP Parameter | Initial ED Setting | Titration Goal | Clinical Rationale |
|---|---|---|---|
| Inspiratory Positive Airway Pressure (IPAP) | 10–12 cmH2O | Titrate by 2 cmH2O up to 18–20 cmH2O | Augments tidal volume and offloads diaphragmatic work of breathing; clears carbon dioxide. |
| Expiratory Positive Airway Pressure (EPAP) | 4–5 cmH2O | Maintain 4–6 cmH2O (do NOT increase aggressively in COPD) | Overcomes intrinsic threshold PEEP to trigger ventilator breaths; excessive EPAP worsens air trapping. |
| FiO2 Titration | Titrate to target SpO2 88–92% | Avoid hyperoxia (SpO2 > 93%) | Hyperoxia in COPD worsens ventilation-perfusion mismatch via loss of hypoxic pulmonary vasoconstriction and the Haldane effect. |
| Success Criteria | Within 1–2 hours | Reduction in respiratory rate (< 25/min), improvement in pH (> 7.30), patient comfort | If patient remains lethargic, acidotic, or exhausted after 1–2 hours, proceed to endotracheal intubation. |
Endotracheal intubation in severe obstructive airway disease is fraught with danger. Positive pressure ventilation easily worsens dynamic hyperinflation, leading to high intrathoracic pressure, decreased venous return, circulatory shock, and tension pneumothorax. Use a dedicated obstructive lung ventilator strategy:
- Low Respiratory Rate: Set rate to 8–10 breaths/min. Maximizes expiratory time to allow complete lung emptying.
- Low Tidal Volume: 6–8 mL/kg of Ideal Body Weight (IBW) (NOT actual body weight).
- High Inspiratory Flow Rate: 70–80 L/min. Delivers the tidal volume rapidly, maximizing the remaining time in the respiratory cycle for exhalation (target I:E ratio of 1:4 or 1:5).
- Low Applied PEEP: Keep external PEEP low (0–5 cmH2O). Excessive external PEEP adds to intrinsic Auto-PEEP and increases alveolar rupture risk.
- Permissive Hypercapnia: Tolerate elevated PaCO2 (60–80 mmHg) and respiratory acidosis down to pH 7.20. Lowering the respiratory rate to protect against dynamic hyperinflation takes precedence over normalizing blood gas values.
- Monitor Plateau Pressure (Pplat): Keep Pplat < 30 cmH2O. High peak inspiratory pressure (PIP) reflects airway resistance, but elevated plateau pressure reflects alveolar overdistention and barotrauma risk.
Critical Pitfall / Contraindication
The Post-Intubation Crash ('DOPES' Protocol): If an intubated asthmatic or COPD patient becomes suddenly hypotensive, bradycardic, or enters cardiac arrest immediately following intubation: 1) DISCONNECT the endotracheal tube from the ventilator immediately; 2) Manually compress the chest to allow trapped air to rush out (relieves tension auto-PEEP); 3) Rule out tension pneumothorax (perform immediate bilateral finger thoracostomies if pulseless); 4) Check for tube dislodgement or cuff herniation; 5) Check for equipment/ventilator malfunction.
In the Fast Track or ambulatory setting, patients frequently present with acute shortness of breath driven by non-life-threatening mechanisms: hyperventilation syndrome, acute viral tracheobronchitis, mild reactive airway flare responding to initial bronchodilator therapy, or vocal cord dysfunction.
| Condition | What to Ask (Key History) | What to Look For (Physical Exam) | Diagnostic Stewardship (Choosing Wisely) | Bedside Treatment & Safe Discharge |
|---|---|---|---|---|
| Hyperventilation Syndrome/Panic Attack | Sudden acute air hunger or feeling unable to get a deep breath, perioral tingling, paresthesias in fingers/toes, intense anxiety. Clear lungs despite severe distress. | SpO2 99–100% on room air; lungs clear bilaterally; rapid shallow thoracic breathing; carpopedal spasm (transient hypocalcemia from acute respiratory alkalosis). | Zero ABG, zero chest CT, zero D-dimer if PERC rule is completely negative (all 8 criteria met with low clinical pretest probability). | Reassurance, coached box breathing (4s in, 4s hold, 4s out, 4s hold). Never use paper bags. Oral hydroxyzine 25 mg PO if needed. Discharge with outpatient counseling referral. |
| Acute Viral Tracheobronchitis | Cough lasting 1–3 weeks following viral URI, retrosternal burning during coughing, mild subjective dyspnea during paroxysms, but comfortable at rest. | Normal vital signs (RR 12–18, HR < 100, Temp < 38°C); SpO2 >= 95%; coarse rhonchi or scattered wheezes that CLEAR with vigorous coughing; zero focal rales or egophony. | Zero chest radiograph indicated if vitals normal and lung exam non-focal. Zero antibiotics (viral etiology; azithromycin provides zero clinical benefit!). | Honey, lozenges, benzonatate (Tessalon Perles) 100–200 mg PO TID. Inhaled albuterol 2 puffs q4–6h PRN for bronchospastic cough. Return precautions for fever > 3 days or worsening dyspnea. |
| Mild Asthma Flare (Rapid Responders) | Known asthmatic with mild wheezing, chest tightness, or cough triggered by cold air or allergen. Speaks in full sentences. | Mild expiratory wheezing in bases; no accessory muscle use; SpO2 >= 95% on room air; Peak Expiratory Flow (PEF) > 70% personal best. | Zero chest X-ray or bloodwork needed for routine mild flare without fever, focal findings, or trauma. | Albuterol 2.5 mg + Ipratropium 0.5 mg nebulized x 1. Oral Dexamethasone 10–12 mg PO single dose (or Prednisone 40–50 mg daily x 5 days). Discharge after 30–60 min observation once asymptomatic with clear lungs and PEF > 70–80%. |
| Vocal Cord Dysfunction (Paradoxical Vocal Fold Motion) | Acute episodic dyspnea and throat tightness in young athletes or high-stress individuals; often misdiagnosed as refractory asthma unresponsive to bronchodilators. | INSPIRATORY wheeze heard loudest over the anterior larynx; lung base auscultation completely clear; SpO2 normal; symptoms improve with distraction or panting. | Chest X-ray normal. Flow-volume loop shows flattened inspiratory curve with normal expiratory curve. | Reassurance. Bronchodilators are ineffective. Speech therapy referral for respiratory retraining (panting, diaphragmatic breathing). Reassure that airway will not obstruct. |
Test Your Acute Severe Asthma & COPD Exacerbation Clinical Acumen
Directly launch an active-recall practice block from our validated question bank with comprehensive explanations and distractor analyses.
Distinguish primary life-threats from mimics. On board exams (COMLEX Level 1, 2-CE, 3 & USMLE), initial stabilizing interventions (airway, IV access, non-invasive ventilation, empiric reversal) always take precedence over diagnostic imaging.
Evaluate autonomic tone: Sympathetic viscerosomatics (T1–L2) cause acute paraspinal tissue texture changes (erythema, bogginess, hypertonicity). Suboccipital release (CN X Vagus) and rib raising normalize autonomic outflow and thoracic cage mechanics.